X0306 4 2015-03-18 0 0001512762 Coherus BioSciences, Inc. CHRS 0001420822 Lanfear Dennis M COHERUS BIOSCIENCES, INC. 201 REDWOOD SHORES PARKWAY, SUITE 200 REDWOOD CITY CA 94065 1 1 0 0 President & CEO Common Stock, $0.0001 par value 2015-03-18 4 J 0 2206 0.00 A 1344926 I By Trust Common Stock, $0.0001 par value 2015-03-18 4 J 0 2084 0.00 A 71635 D Common Stock, $0.0001 par value 2015-03-18 4 J 0 13 0.00 A 86965 I By LLC On March 18, 2015, Reporting Person, his Trust and LLC became entitled to receive shares of Issuer's common stock pursuant to an "earn out" provision included in that certain Agreement and Plan of Merger by and among Issuer, Coherus Intermediate Corp., Coherus Acquisition Corp., InteKrin Therapeutics Inc. ("InteKrin") and Fortis Advisors LLC, dated as of January 8, 2014 (the "Merger Agreement"), pursuant to which Issuer acquired all outstanding common stock of InteKrin on January 8, 2014. The Merger Agreement provided that stockholders of InteKrin would receive additional shares of Issuer's common stock, for no additional consideration, upon the first dosing of a patient with INT 131 (the "Milestone"). The Milestone occurred on March 6, 2015, and as a result an earn out payment of an aggregate of 358,384 shares of Issuer's common stock was executed by the escrow agent and transfer agent on March 18, 2015 upon determination that all conditions for such release had been satisfied. These shares are held by the Lanfear Revocable Trust, dated January 27, 2004, as restated, of which Reporting Person is a trustee. These shares are held by Lanfear Capital Advisors, LLC of which Reporting Person is President. /s/ Matthew R. Hooper, as Attorney-in-Fact for Dennis M. Lanfear 2015-03-18